Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

SRR658645

GTEX

bc358ecb-ebad-5837-a500-00d23394ed58

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
—
subtype
—
cancer_type
GTEX
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.428
  • INFLAMMATORY_RESPONSE+0.353
  • IL6_JAK_STAT3_SIGNALING+0.270
  • MYOGENESIS+0.268
  • SPERMATOGENESIS+0.259
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.239
  • KRAS_SIGNALING_UP+0.236
  • ALLOGRAFT_REJECTION+0.216
  • COAGULATION+0.199
  • APICAL_SURFACE+0.176

Top 10 suppressed

  • MYC_TARGETS_V1-0.628
  • OXIDATIVE_PHOSPHORYLATION-0.570
  • DNA_REPAIR-0.497
  • MTORC1_SIGNALING-0.473
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.472
  • UNFOLDED_PROTEIN_RESPONSE-0.458
  • MYC_TARGETS_V2-0.437
  • E2F_TARGETS-0.435
  • CHOLESTEROL_HOMEOSTASIS-0.428
  • PROTEIN_SECRETION-0.427

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1486863
brain-umap@2
GTEX—0.952
2SRR1362464
brain-umap@2
GTEX—0.950
3SRR820292
brain-umap@2
GTEX—0.946
4SRR1331289
brain-umap@2
GTEX—0.946
5SRR1459423
brain-umap@2
GTEX—0.944
6SRR1418604
brain-umap@2
GTEX—0.943
7SRR1429957
brain-umap@2
GTEX—0.942
8SRR817758
brain-umap@2
GTEX—0.938
9SRR1320012
brain-umap@2
GTEX—0.938
10SRR819793
brain-umap@2
GTEX—0.935

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.428Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.353Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.270Inavolisib— uncovered
MYOGENESIS0.268Inavolisib— uncovered
SPERMATOGENESIS0.259Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.239Inavolisib— uncovered
KRAS_SIGNALING_UP0.236Inavolisib— uncovered
ALLOGRAFT_REJECTION0.216Idelalisib— uncovered
COAGULATION0.199Binimetinib— uncovered
APICAL_SURFACE0.176Temsirolimus— uncovered
HEDGEHOG_SIGNALING0.176Inavolisib— uncovered
COMPLEMENT0.150Inavolisib— uncovered
ANGIOGENESIS0.139Remibrutinib— uncovered
BILE_ACID_METABOLISM0.116Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.102Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.088Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.078Inavolisib— uncovered
IL2_STAT5_SIGNALING0.072Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.067Inavolisib— uncovered
UV_RESPONSE_DN0.053Inavolisib— uncovered